John E. Flaherty
Jonathan M. H. Short

McCarter & English, LLP
Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07102
T (973) 622-4444
F (973) 624-7070

Attorneys for all Plaintiffs

Of Counsel:

Eric J. Lobenfeld

Arlene L. Chow

Dillon Kim

HOGAN LOVELLS US LLP 875 Third Avenue

New York, New York 10022

(212) 010 2000

(212) 918-3000

Attorneys for all Plaintiffs

Philippe Y. Riesen

HOGAN LOVELLS HORITSU

JIMUSHO

Gaikokuho Kyodo Jigyo 15th Floor Daido Seimei Kasumigaseki Building

1-4-2 Kasumigaseki

Chiyoda-ku, Tokyo 100-0013 Japan

(81) 3-5157-8200

Attorney for all Plaintiffs

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

TAKEDA PHARMACEUTICAL

COMPANY LIMITED, TAKEDA

PHARMACEUTICALS NORTH AMERICA,
INC., TAKEDA PHARMACEUTICALS

LLC, TAKEDA PHARMACEUTICALS

AMERICA, INC., and ETHYPHARM, S.A.,

Plaintiffs and Counterclaim-Defendants,

٧.

ZYDUS PHARMACEUTICALS (USA) INC. and CADILA HEALTHCARE LIMITED,

Defendants and Counterclaim-Plaintiffs.

Civil Action No. 3:10-CV-01723-JAP-TJB

REPLY BRIEF IN SUPPORT OF
TAKEDA'S MOTION FOR SPOLIATION
SANCTIONS IN THE FORM OF
EXCLUSION OF ZYDUS' EVIDENCE OF
PARTICLE SIZE TESTING ON
PRE-TABLETED GRANULES

CONFIDENTIAL – TO BE FILED UNDER SEAL

TABLE OF CONTENTS

		<u>Page</u>
PRELIMINAR	Y STATEMENT	1
ARGUMENT.		3
Α.		
		2
		3
В.		
		4
C.		_
D.	The Court Can Rely on Its Inherent Authority to Issue Sanctions	8
CONCLUSION	N	9

TABLE OF AUTHORITIES

CASES	Page(s)
Eisai Co. v. Teva Pharms. USA, Inc., 247 F.R.D. 440 (D.N.J. 2007)	6
In re Gabapentin Patent Litig., 214 F.R.D. 178 (D.N.J. 2003)	6
Medeva Pharma Suisse A.G. v. Roxane Labs., Inc., Civil Action No. 07-5165 (FLW), 2011 WL 310697 (D.N.J. Jan. 28, 2011) (Bongiovanni, J.)	7, 8
Mosaid Techs. Inc. v. Samsung Elecs. Co., Ltd., 348 F. Supp. 2d 332 (D.N.J. 2004)	3, 8
Sanofi-Aventis Deutschland GmbH v. Glenmark Pharms. Inc., USA, Civil Action No. 07-CV-5855 (DMC-JAD), 2010 WL 2652412 (D.N.J. July 1	, 2010)7
Schering Corp. v. Apotex Inc., No. 09-6373 (PGS) (D.N.J. Mar. 7, 2012) (Bongiovanni, J.)	4

The Takeda Plaintiffs¹ ("Takeda") submit this reply brief in support of their motion for spoliation sanctions against Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited (together, "Zydus").


PRELIMINARY STATEMENT


Zydus argues there has been no spoliation because
Lydus' argument boils down to "I fed my homework
to the dog, and I didn't know I had to turn my homework in anyway."
First, spoliation is not limited to destruction of evidence. Spoliation includes failure to
preserve evidence.
Second, Paragraph IV certifications trigger
subsequent Hatch-Waxman patent litigation, and Zydus knows this well.
subsequent rate. Walking parent hugawan, and 15, and 110 we have
·

¹ The Takeda Plaintiffs are Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceuticals LLC, and Takeda Pharmaceuticals America, Inc.



² See Takeda's Opposition to Zydus' Motion for Leave to Amend Its Invalidity and Non-Infringement Contentions, D.I. 148,






⁴ This Court's recent decision in *Schering Corp. v. Apotex Inc.*, No. 09-6373 (PGS) (D.N.J. Mar. 7, 2012) (Bongiovanni, J.), attached as Ex. 1, is not to the contrary. In that case, this Court denied plaintiff's spoliation motion because plaintiff inexplicably delayed four months in raising the issue until one month before trial. *Id.* at 1-2. Here, by contrast, Takeda filed its motion promptly,


Because "time certainly is of the essence" in "cases such as this," sanctions here are warranted to preserve the case schedule. *Id.* at 2. Takeda is bringing this motion to ensure that the 30 month stay is not endangered.




⁵ See Notice Letter (Feb. 19, 2010) at 62, attached as Ex. 2; Defendants' Non-infringement and Invalidity Contentions (Aug. 16, 2010) (Ex. 3); Defendants' Amended Non-infringement and Invalidity Contentions (Dec. 3, 2010) (Ex. 4).



First, Paragraph IV certifications and patent litigation go hand-in-hand; there is a well-established, statutorily-mandated cause-and-effect between a Paragraph IV certification and a subsequent suit for patent infringement.⁷



⁷ See, e.g., Eisai Co. v. Teva Pharms. USA, Inc., 247 F.R.D. 440, 442 (D.N.J. 2007) ("Thus, when Teva sent its Notice Letter, it must have anticipated that Eisai would file suit before the statutory deadline. Given the cause-and-effect between a Paragraph IV Certification and a subsequent suit for infringement, this Court finds that the retention of an expert with an eye towards filing such a Certification is done in anticipation of litigation."); In re Gabapentin



Patent Litig., 214 F.R.D. 178, 185 (D.N.J. 2003) ("Simply stated, litigation (in the form of a patent infringement action) is almost certain to follow a Paragraph IV Certification.")

⁸ See Sanofi-Aventis Deutschland GmbH v. Glenmark Pharms. Inc., USA, Civil Action No. 07-CV-5855 (DMC-JAD), 2010 WL 2652412, at *3, 5 (D.N.J. July 1, 2010) (observing that '[o]nce a party reasonably anticipates litigation, it must suspend its routine document retention/destruction policy and put in place a 'litigation hold' to ensure the preservation of relevant documents' and concluding that defendants' "duty to impose a litigation hold and to institute legal monitoring for purposes of compliance arose no later than February 23, 2006," when defendants first asserted work product immunity) (citation omitted); Medeva Pharma Suisse A.G. v. Roxane Labs., Inc., Civil Action No. 07-5165 (FLW), 2011 WL 310697, at *15 (D.N.J. Jan. 28, 2011) (Bongiovanni, J.) ("[T]he court cannot fathom why Roxane failed to institute a litigation hold . . . perhaps as far back as July 31, 2001 if its privilege log claiming work product protection over a document with that date is to be credited").

Moreover, the Takeda and Ethypharm Orange Book-listed patents are formulation patents; infringement or non-infringement is highly dependent on the specific formulation at issue. The fact that Teva may have designed around the Takeda and Ethypharm patents with its ODT formulation has no bearing whatsoever on whether or not Zydus' separate and distinct ODT formulation infringes. In fact, Takeda did not assert the Takeda patents against Teva at the claim construction, expert and trial phases of the case. In sharp contrast, Takeda has asserted the Takeda patents against Zydus at the claim construction and expert phases thus far; Takeda anticipates asserting those patents at trial as well.

D. The Court Can Rely on Its Inherent Authority to Issue Sanctions

Zydus argues, at length, that sanctions are somehow barred because Takeda did not previously move to compete See Opp. Br. at p. 14-17 (citing to Fed. R. Civ. P. 37). Zydus is wrong. A court order does not bring back that which has already been destroyed. A motion to compel is hardly requisite for sanctions here; the Court can impose spoliation sanctions pursuant to its inherent authority as well as the Federal Rules of Civil Procedure. See Mosaid Techs. Inc. v. Samsung Elecs. Co., 348 F. Supp. 2d 332, 335 (D.N.J. 2004) ("This Court has the authority to impose spoliation sanctions pursuant to the Federal Rules of Civil Procedure and this Court's inherent authority."); Medeva Pharma Suisse A.G. v. Roxane Labs., Inc., Civil Action No. 07-5165 (FLW), 2011 WL 310697, at *14 (D.N.J. Jan. 28, 2011) (Bongiovanni, J.) ("The Court has authority to impose spoliation sanctions pursuant to both the Federal Rules of Civil Procedure and its inherent authority, and the choice of which sanction should be imposed rests in the sound discretion of the Court.").

_		
_		
	CONCLUSION	-
	CONCLUSION	
7	Because Zydus has unquestionably failed to preserve evidence when it knew that	
gati	•	
gati	Because Zydus has unquestionably failed to preserve evidence when it knew that	•
	Because Zydus has unquestionably failed to preserve evidence when it knew that on was reasonably foreseeable, it should not be able to benefit from that evidence Zydus' spoliation severely prejudices Takeda and	warı
nctio	Because Zydus has unquestionably failed to preserve evidence when it knew that on was reasonably foreseeable, it should not be able to benefit from that evidence	w arr

Respectfully submitted,

Dated: March 12, 2012

By: s/John E. Flaherty
John E. Flaherty
Jonathan M.H. Short
MCCARTER & ENGLISH, LLP
Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07102
(973) 622-4444

Attorneys for all Plaintiffs

OF COUNSEL: Eric J. Lobenfeld Arlene L. Chow Dillon Kim HOGAN LOVELLS US LLP 875 Third Avenue New York, New York 10022 (212) 918-3000

Philippe Y. Riesen

HOGAN LOVELLS HORITSU JIMUSHO
Gaikokuho Kyodo Jigyo
15th Floor Daido Seimei
Kasumigaseki Building
1-4-2 Kasumigaseki
Chiyoda-ku, Tokyo 100-0013 Japan
(81) 3-5157-8200

Attorneys for all Plaintiffs

CERTIFICATE OF SERVICE

The undersigned hereby certifies that true copies of the foregoing REPLY BRIEF IN

SUPPORT OF TAKEDA'S MOTION FOR SPOLIATION SANCTIONS IN THE FORM OF

EXCLUSION OF ZYDUS' EVIDENCE OF PARTICLE SIZE TESTING ON PRE-TABLETED

GRANULES and supporting documents were caused to be served on March 12, 2012 via email

and/or the ECF system upon all counsel of record.

By: <u>s/John E. Flaherty</u>

John E. Flaherty

11